Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CETP | P11597 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | LAP3 | P28838 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KLK1 | P06870 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389180 | 0.86 | TSHR (0.63) | TSHRPKMCETPSRC | |
| SCHEMBL18214656 | 0.83 | CA1 (0.54) | TSHRMEN1HTTKMT2A | |
| SCHEMBL17400975 | 0.82 | NR4A2 (0.61) | MEN1KMT2A | |
| SCHEMBL27254359 | 0.82 | PKM (0.54) | PKMMEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL9568480 | 0.81 | TSHR (0.57) | TSHRMEN1HTTKMT2ACETP | |
| SCHEMBL381492 | 0.81 | TSHR (0.57) | TSHRMEN1HTTKMT2ACETP | |
| SCHEMBL10885712 | 0.81 | L3MBTL1 (0.52) | PKMMEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL8619121 | 0.81 | TSHR (0.57) | TSHRPKMCETPSRCLAP3 | |
| SCHEMBL310184 | 0.80 | SRC (0.58) | PKMMEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL17034260 | 0.79 | TSHR (0.55) | TSHRPKMMEN1KMT2ACETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| CN-107078352-B | Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery using same | 三菱化学株式会社 | 2020-04-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | NUDT1, PNP, ATIC | TSHR 3475/4885PKM 2510/4885MEN1 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.